Waksman R, et al. - Experts intended to assess the safety and efficiency of the bioresorbable-polymer sirolimus-eluting stent (BP-SES) in subjects with diabetes mellitus (these subjects are likely to have increased adverse outcomes following a percutaneous coronary intervention, even with contemporary drug-eluting stents). Patient-level data from the BIOFLOW II, IV, and V randomized controlled trials were merged in order to ascertain the performance of the BP-SES in diabetic subjects. Target lesion failure (TLF), described as the composite of cardiovascular death, target vessel myocardial infarction, ischemia-driven target lesion revascularization, and definite or probable stent thrombosis, was the primary endpoint at 1 year. Seven hundred and fifty-seven diabetic patients were recognized from 1,553 BP-SES and 791 durable-polymer everolimus-eluting stent (DP-EES) subjects. The proportion of insulin- and non-insulin-treated subjects was alike among groups of the diabetic subjects involved in this analysis. The 1-year TLF rate in the diabetic population was 6.3% and 8.7% in the BP-SES group and in the DP-EES group, respectively. On the basis of the stent type or diabetes treatment regimen, no significant differences in TLF hazards could be ascertained. Moreover, 1-year clinical safety and effectiveness outcomes were alike amongst subjects who treated with ultrathin BP-SES and thin-strut DP-EES, in a patient-level pooled analysis of the diabetic community from randomized trials.